Overview

Qlaris Phase 2 Study of QLS-111 in POAG and/or OHT Patients

Status:
Recruiting
Trial end date:
2024-09-05
Target enrollment:
Participant gender:
Summary
Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in primary open-angle glaucoma (POAG) or ocular hypertension patients.
Phase:
Phase 2
Details
Lead Sponsor:
Qlaris Bio, Inc.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions